Opponents use aducanumab approval to try to derail Woodcock nomination as FDA commissioner

Long-time opponents of Acting FDA Commissioner Janet Woodcock cited the accelerated approval of Biogen’s aducanumab for Alzheimer’s disease in letters urging President Joe Biden not to nominate her to the job on a permanent basis.

Sen. Joe Manchin (D-W. Va.), who has publicly and privately pushed back since January against nominating Woodcock for the position, citing concerns over her role in regulating opioids, added Aduhelm aducanumab from  Biogen Inc. (NASDAQ:BIIB) to his list of concerns in a letter released Thursday. ...